Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NDM
|
|||
| Former ID |
DAP000407
|
|||
| Drug Name |
Paromomycin
|
|||
| Synonyms |
Aminosidin; Catenulin; Humatin; Hydroxymycin sulfate; Paramomycin Sulfate; Paromomycin I; Paromomycin sulfate Rx346208; Aminosidine, sulfate; HATT & Paromomycin; Humatin (TN); Paromomycin (INN); Paromomycin (TN); Paromomycin (complex); PA1-PA2-PA3-PA4; Human .alpha.-1-antitrypsin & Paromomyin; PAROMOMYCIN I, AMMINOSIDIN, CATENULIN, CRESTOMYCIN, MONOMYCIN A, NEOMYCIN E; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside; (2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol; O-2-Amino-2-deoxy-.alpha.-D-glucopyranosyl-(1->4)-O-[O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1->3)-.beta.D-ribofuranosyl(1->5)]-2-deoxy-D-streptamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Intestinal amebiasis [ICD-11: 1A36; ICD-10: A06, A06.9; ICD-9: 6] | Approved | [1] | |
| Therapeutic Class |
Antibiotics
|
|||
| Company |
King Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H45N5O14
|
|||
| Canonical SMILES |
C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N
|
|||
| InChI |
1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
|
|||
| InChIKey |
UOZODPSAJZTQNH-LSWIJEOBSA-N
|
|||
| CAS Number |
CAS 7542-37-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4090, 600745, 629812, 7889687, 7889708, 7980252, 10255961, 24380735, 25628810, 26705725, 26707026, 26707296, 26718034, 26718038, 26718087, 26718092, 26737833, 26737866, 29195990, 29196150, 46239584, 46505391, 48416383, 49693301, 49693302, 49703371, 49829578, 49829580, 50139565, 56313066, 57350802, 76778425, 96024433, 104234223, 113456730, 123059634, 123059983, 126645008, 127294526, 127294527, 127294528, 127294529, 134213896, 134213903, 134337703, 135874467, 136349017, 136349597, 137004588, 143073336
|
|||
| ChEBI ID |
CHEBI:7934
|
|||
| ADReCS Drug ID | BADD_D01677 ; BADD_D01678 | |||
| SuperDrug ATC ID |
A07AA06
|
|||
| SuperDrug CAS ID |
cas=007542372
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was increased by Paromomycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Holdemania
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Holdemania was increased by Paromomycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Blautia was decreased by Paromomycin. | |||
|
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridium was decreased by Paromomycin. | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Coprococcus was decreased by Paromomycin. | |||
|
Studied Microbe: Faecalibacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Luminal, mucosa | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Faecalibacterium was decreased by Paromomycin. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) | Target Info | Binder | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171. | |||
| REF 2 | Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin. Gut Microbes. 2015 Jul 4;6(4):243-54. | |||
| REF 3 | Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. | |||
| REF 4 | 30S ribosomal subunit assembly is a target for inhibition by aminoglycosides in Escherichia coli. Antimicrob Agents Chemother. 2002 May;46(5):1546-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.